NLS Pharmaceutics Ltd. (NASDAQ:NLSP) is a Swiss clinical-stage biopharmaceutical company. It focuses on developing therapies for rare and complex central nervous system disorders. The company is preparing for a significant transition, including a reverse stock split and a merger with Kadimastem Ltd., an Israeli biotechnology firm.
The reverse stock split, scheduled for October 31, 2025, will consolidate every 10 shares of NLSP into 1 share. This move is part of the company's strategy to enhance its market position. The stock is currently priced at $0.74, having decreased by 29.52% recently. The merger with Kadimastem Ltd. will result in a name change to NewcelX Ltd., with the new symbol "NCEL" on the Nasdaq Capital Market.
This merger aims to expand NLS Pharmaceutics' capabilities in its specialized field. The new CUSIP number for the shares post-merger and reverse split will be H5835A109. NLSP's stock has seen a low of $0.74 and a high of $0.94 today. Over the past year, it reached a peak of $4.74 and a low of $0.74. The company's market capitalization is approximately $2.34 million, with a trading volume of 1,409,410 shares, as highlighted by the recent trading data.
